433939-83-4

Upstream product

• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 942282-42-0 2-fluoro-4-(2-hydroxyethyl)benzonitrile 
• 85070-67-3 2-fluoro-4-methylbenzonitrile 
• 1097871-99-2 (4-cyano-3-fluorophenyl)acetic acid 
• 1255207-56-7 2-(4-cyano-3-fluorophenyl)ethyl methanesulfonate 
• 7486-35-3 tri-n-butyl(vinyl)tin 

Downstream Products

• 1255207-55-6 2-fluoro-4-oxiran-2-ylbenzonitrile 
• 222978-02-1 2-fluoro-4-(hydroxymethyl)benzonitrile 

Relevant academic research and scientific papers

CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS

The present disclosure provides pyrimidine dione compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors. The compounds can be used alone or in combination with other anti-cancer agents.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula(I) or a pharmaceutically acceptable salt thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure, kidney disease, edema, and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure

Mandelic acid derivatives and their use as throbin inhibitors

There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.